{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-075416","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.942318+00:00","generated_at":"2026-06-10T22:20:30.845411+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phoenix Biotech receives Nasdaq deficiency notice for minimum public holders rule","bullets":["Received Nasdaq notice on Sep 7, 2023, for non-compliance with Minimum Public Holders Rule (400 public holders required for Nasdaq Global Market).","Has 45 calendar days to submit a plan to regain compliance; intends to submit within timeframe.","If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, can appeal to Hearings Panel.","Also pursuing a business combination with CERo Therapeutics (previously filed Form S-4).","Notice is not an imminent delisting; no current effect on listing or trading of PBAX securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-075416","json":"https://secwatch.observer/filing/0001213900-23-075416.json","markdown":"https://secwatch.observer/filing/0001213900-23-075416.md","text":"https://secwatch.observer/filing/0001213900-23-075416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/0001213900-23-075416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/ea184886-8k425_phoenix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:20:30.845411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55040982a16931fee74ad1ba5ad9d0f2a2b71fa9","claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).","evidence_excerpt":"September 7, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(a)(2), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s se","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/0001213900-23-075416-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Rules","value":"5450(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}